FeesSafety
Pluang+

SI-BONE Q3 revenue rises 15% to $55.7M; new Onyx device expands market to $5B

Company Fundamentals
23 Nov 2026, 04:57 WIB
The Motley Fool Team
View Source
Bullish
SI-BONE Q3 revenue rises 15% to $55.7M; new Onyx device expands market to $5B

SI-BONE reported a 15% increase in third-quarter 2026 revenue to $55.7 million, driven by growing adoption of its surgical implants. The launch of the iFuse Granite Onyx device, approved by the FDA, expands the company's addressable market to $5 billion by targeting spinal fusion failures. Higher Medicare reimbursement rates for complex spinal surgeries are expected to boost hospital adoption, while the active physician base grew 16% to 1,770 doctors, enhancing commercial reach. The company is optimistic about accelerating growth, improving profitability, and expanding patient outcomes.

SI-BONE's recent developments provide context for readers interested in health-related stocks. For readers following this sector, here is Pluang's market snapshot as of Nov 23, 2026 03:02 WIB: Among 150 priced health-sector US stocks, 31 rose and 117 fell today. FLNA gained 14.52% to USD 0.64 with a typical hold time of 39 days, contrasting sharply with NUWE and CGC which dropped 10.50% and 9.97% to USD 3.41 and USD 0.43 respectively, with hold times around 35-40 days.

More News

Nvidia, Coherent, and Dell report strong AI-driven growth despite recent stock drops.

Nvidia, Coherent, and Dell report strong AI-driven growth despite recent stock drops.

Nvidia, Coherent, and Dell Technologies all supply key components for AI infrastructure and have reported strong revenue growth despite significant stock price declines. Nvidia's data center revenue rose 21% sequentially, with a fiscal Q4 revenue for...

Bullish
19 minutes ago
BridgeBio's Attruby revenue soars 134% YoY; FDA decision for BBP-418 due Nov 27

BridgeBio's Attruby revenue soars 134% YoY; FDA decision for BBP-418 due Nov 27

BridgeBio reported a 134% year-over-year increase in net product revenue for Attruby, reaching $253.2 million in Q3 2026, driven by new patients starting treatment for transthyretin amyloid cardiomyopathy. The company anticipates an FDA decision on N...

Company Fundamentals
Bullish
47 minutes ago
Altria raises dividends for 57 years but faces declining cigarette sales and high payout risks.

Altria raises dividends for 57 years but faces declining cigarette sales and high payout risks.

Altria Group has increased its dividends for 57 consecutive years, maintaining a strong yield of 5.9%, well above the S&P 500 average. However, the company's cigarette sales volumes continue to decline, with a 2.8% drop in cigarette volume this year ...

Company Fundamentals
Neutral
48 minutes ago
Everforth's Q3 revenue tops $1B; cybersecurity bookings surge 40% amid rising AI adoption.

Everforth's Q3 revenue tops $1B; cybersecurity bookings surge 40% amid rising AI adoption.

Everforth reported $1.03 billion in revenue for Q3 2026, surpassing company guidance. The firm sees enterprise software as the key channel for AI deployment, with strong growth in cybersecurity and risk bookings, up over 40% year-to-date due to incre...

Company Fundamentals
Bullish
1 hour ago
Regional Management Q3 revenue hits $179M; auto loans grow 25%, bank partnerships boost margins.

Regional Management Q3 revenue hits $179M; auto loans grow 25%, bank partnerships boost margins.

Regional Management reported $179 million in revenue for Q3 2026, driven by expanding bank partnerships and a 25% year-over-year increase in auto-secured loans. The company is tightening credit on high-risk digital loans and shifting focus to auto-se...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App